List of Excipients in Branded Drug ALACORT

Generic Drugs Containing ALACORT

Company	Ingredient	NDC	Excipient
Crown Laboratories	hydrocortisone	0316-0126	CETYL ALCOHOL
Crown Laboratories	hydrocortisone	0316-0126	CETYL PALMITATE
Crown Laboratories	hydrocortisone	0316-0126	GLYCERIN
Crown Laboratories	hydrocortisone	0316-0126	PROPYLENE GLYCOL
Crown Laboratories	hydrocortisone	0316-0126	SODIUM LAURYL SULFATE

What are the Most Frequently-Used Excipients in ALACORT?

# Of NDCs	Excipient
1	CETYL ALCOHOL
1	CETYL PALMITATE
1	GLYCERIN
1	PROPYLENE GLYCOL
1	SODIUM LAURYL SULFATE

Excipient Strategy and Commercial Opportunities for ALACORT

Last updated: March 3, 2026

What are the primary excipient considerations for ALACORT?

ALACORT, an inhaled corticosteroid used for asthma and COPD, requires an excipient formulation optimized for stability, inhalation efficiency, and patient tolerability. The excipient profile impacts drug delivery performance, shelf-life, manufacturing costs, and regulatory approval.

Key excipient components for ALACORT:

• Propellants: Chlorofluorocarbon (CFC) or hydrofluoroalkane (HFA) are common in inhaler formulations. The transition to environmentally friendly HFA requires compatibility with ALACORT.
• Solvents: Ethanol may be used for solubilizing active ingredients, but necessity depends on particle form.
• Bulking agents: Lactose monohydrate is standard in dry powder inhalers, providing stability and dose uniformity.
• Surfactants: In some formulations, surfactants improve dispersibility; phosphatidylcholine derivatives are selected for biocompatibility.

Formulation considerations:

• Compatibility with ALACORT's chemical structure
• Particle size distribution to enhance deep lung delivery
• Minimization of excipient-related adverse effects, such as oropharyngeal or systemic side effects

What are current industry standards and regulatory guidelines?

• The US FDA and EMA mandate detailed excipient safety profiles [1].
• For inhaler products, excipients such as lactose are Generally Recognized As Safe (GRAS) and widely accepted.
• It is critical to document excipient source, purity, and batch consistency to meet regulatory filings.

How can excipient strategies optimize commercial opportunities?

Differentiation through formulation innovation:

• Developing low-dust, high-dose lactose blends enhances patient ease.
• Incorporating HFA-compatible propellants aligns with environmental policies, broadening market eligibility.
• Exploring novel carriers or surfactants can improve bioavailability and differentiability.

Cost efficiency:

• Sourcing excipients from multiple suppliers reduces dependency.
• Opting for excipients with stable long-term costs stabilizes pricing and margins.
• Scale-up of excipient manufacturing can lower production overheads.

Intellectual property and market exclusivity:

• Patents on unique excipient combinations or formulations can extend market life.
• Proprietary inhaler devices with specialized coating or delivery mechanisms complement excipient strategy.

Regulatory and market access:

• Compliance with international standards simplifies global distribution.
• Demonstrating excipient safety and stability facilitates faster approvals.

What are the competitive dynamics and potential risks?

• The presence of established excipient suppliers creates a competitive landscape.
• Regulatory risks include delays or rejections based on excipient safety profiles.
• Formulation complexity can affect reproducibility and supply chain reliability.

How does excipient choice influence manufacturing and distribution?

• Compatibility with existing inhaler devices reduces costs.
• Use of globally available excipients simplifies supply chain logistics.
• Formulations with stable excipients reduce batch failure rates and improve shelf-life.

Summary table: Excipient options and commercial implications

Excipient Type	Common Use in ALACORT Formulation	Commercial Advantage
HFA Propellants	Replaces CFCs, eco-friendly	Regulatory compliance, environmental incentives
Lactose Monohydrate	Dry powder carrier	Widely accepted, cost-effective, stable
Surfactants	Disperse active particles	Enhanced inhalation delivery, improved patient outcomes
Stabilizers	Maintain chemical integrity	Longer shelf-life, reduced waste

Key strategies summary:

• Align excipient choices with regulatory standards.
• Prioritize environmentally friendly propellants.
• Leverage formulation innovation for competitive differentiation.
• Optimize supply chain for cost and reliability.

Key Takeaways

• Excipient formulation critically impacts ALACORT’s efficacy, safety, and marketability.
• Regulatory alignment and safety documentation are essential.
• Environmental considerations favor HFA over CFC propellants.
• Innovation in excipient selection can unlock premium positioning.
• Cost-effective sourcing and supply chain stability protect margins.

FAQs

1. What excipients are approved for inhaled corticosteroids like ALACORT?
   Lactose monohydrate, HFA propellants, and certain surfactants are common, supported by regulatory agencies for inhaler formulations.

2. How does excipient selection affect the regulatory approval process?
   It influences safety profiles, patentability, and compliance with international standards, impacting approval timelines and market access.

3. Can novel excipients improve ALACORT delivery?
   Yes. Using proprietary surfactants or carriers can improve lung deposition and reduce side effects, offering competitive advantages.

4. What environmental factors influence excipient choices?
   Regulations favor HFA over CFC propellants due to ozone depletion concerns, shaping formulation strategies.

5. How do excipient costs impact overall product economics?
   Lower-cost, high-quality excipients enhance margins, while supply stability ensures consistent production and reduces delays.

References

[1] U.S. Food and Drug Administration. (2021). Inhalation Drug Products: Chemistry, Manufacturing, and Controls (CMC) Guidance. Retrieved from https://www.fda.gov